Stockreport

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM) [Yahoo! Finance]

Aytu BioPharma, Inc.  (AYTU) 
NASDAQ:AMEX Investor Relations: aytubio.com/investors/stock-information
PDF Full year fiscal 2025 adjusted EBITDA of $9.2 million $31.0 million cash balance at June 30, 2025 Exclusive agreement in June 2025 to commercialize EXXUA™ (ge [Read more]